The FDA has approved updated labeling for Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy for dystrophic epidermolysis bullosa.

The ACIP voted to recommend that the combined MMRV vaccine not be given before age 4 years and will vote on the hepatitis B vaccine Friday.

Skin cancer risk was significantly reduced with nicotinamide initiation and more so with initiation after a first skin cancer.

Topical ruxolitinib does not carry the same safety profile as oral JAK inhibitors for AD, which may warrant reconsideration of the boxed warning.

DermaRite Industries widened its recall of personal care products contaminated with Burkholderia cepacia complex.

Officials from the Centers for Medicare and Medicaid Services moved to close Miami’s Life Alliance Organ Recovery Agency over safety issues.

Patients with protoporphyria experience high rates of impaired daily function, emotional and psychosocial distress, and health care use.

The FDA analyzed possible birth defects after vaccination during pregnancy and deaths in children following COVID vaccination.

Compared with staples alone, staples plus iNPWT significantly reduced the risk for SSI and wound dehiscence in patients who underwent laparotomy.

Tralokinumab self-administered by patients with atopic dermatitis via a pre-filled pen is a safe and effective treatment option.

A majority of cancer drugs approved in the US during 2019-2022 had “clinical trial uncertainties,” research suggests.

Suicidal ideation was reported by 13.2% of patients with atopic eczema compared with 8.5% of those without atopic eczema.